Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous concentrated bone marrow cell product
- Development stage
- Unknown
- Lead developer
- Olympus Terumo Biomaterials
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraosseous
01
Overview
Autologous concentrated bone marrow cell product is a regenerative medicine therapy developed by Olympus Terumo Biomaterials for the treatment of idiopathic osteonecrosis of the femoral head (ONFH). The product is prepared by harvesting bone marrow from the patient's iliac bone and concentrating the mononuclear cell fraction, which is rich in mesenchymal stem cells (MSCs) and hematopoietic stem cells. This concentrate is then implanted into the necrotic area of the femoral head, where the cells differentiate into osteoblasts and secrete angiogenic and osteogenic growth factors, such as vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs). This process facilitates the regeneration of bone tissue and improves local blood supply, thereby preventing the collapse of the femoral head and the progression of the disease. It was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) in February 2024.
- Other names
- Autologous concentrated bone marrow cellsConcentrated bone marrow aspirateBMACAutologous bone marrow mononuclear cells
Beyond the preview
Go deeper on autologous concentrated bone marrow cell product.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous concentrated bone marrow cell product.